Get the Stockscreener App
0.88
3.24%
-0.0295
After Hours:
.88
Hoth Therapeutics Inc stock is traded at $0.88, with a volume of 64,846.
It is down -3.24% in the last 24 hours and up +26.82% over the past month.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
See More
Previous Close:
$0.9095
Open:
$0.94
24h Volume:
64,846
Relative Volume:
0.02
Market Cap:
$6.08M
Revenue:
-
Net Income/Loss:
$-9.62M
P/E Ratio:
-0.1415
EPS:
-6.22
Net Cash Flow:
$-7.93M
1W Performance:
-3.65%
1M Performance:
+26.82%
6M Performance:
-42.11%
1Y Performance:
-42.12%
1-Day Range:
$0.87
$0.94
1-Week Range:
$0.84
$0.94
52-Week Range:
$0.58
$1.73
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
590 MADISON AVENUE, NEW YORK, NY
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Significant Increase in Short Interest - Defense World
EGFR Inhibitors-Induced Skin Disorders Market Growth - openPR
Buy Honasa Consumer, target price Rs 530: JM Financial - The Economic Times
Examining the Potential Price Growth of Holley Inc (HLLY) - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Harrow Inc (HROW) Becoming More Attractive for Investors - Knox Daily
Davidson Kempner Capital Management LP Invests $3.21 Million in Loar Holdings, LLC (NYSE:LOAR) - Defense World
Why Investors Shouldn't Be Surprised By THOR Industries, Inc.'s (NYSE:THO) P/E - Simply Wall St
Lombard Odier Asset Management USA Corp Invests $786,000 in Hilton Grand Vacations Inc. (NYSE:HGV) - Defense World
THG Plunges 24% ATO amid Internal Frauds by Subsidiaries - KAOHOON INTERNATIONAL
Holley Inc. (NYSE:HLLY) Shares Sold by Kayne Anderson Rudnick Investment Management LLC - Defense World
Capstone Triton Financial Group LLC Has $707,000 Stock Position in Honeywell International Inc. (NASDAQ:HON) - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Trading Down 3% - Defense World
Highbridge Capital Management LLC Purchases Shares of 630,114 HashiCorp, Inc. (NASDAQ:HCP) - MarketBeat
Haoxi Health Technology Down 75% After $12M Offering - MarketWatch
The time has not yet come to remove your chips from the table: Hoth Therapeutics Inc (HOTH) - SETE News
Hoth Therapeutics Inc (HOTH) gets rating Initiated from The Benchmark Company - Knox Daily
Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News
Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Choreo LLC Purchases New Shares in The Hanover Insurance Group, Inc. (NYSE:THG) - Defense World
C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register
Hoth Therapeutics Inc (HOTH) Stock: Navigating a Year of Volatility - The InvestChronicle
Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - PR Newswire
Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal
Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex
Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News
Relay Therapeutics Shows Promising Results with RLY-2608 in Breast Cancer Study - BP Journal
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal
Hoth Therapeutics Inc: Rising -68.55% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Are Hoth Therapeutics Inc’shares a good deal? - US Post News
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - MSN
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Zacks Investment Research
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - Yahoo Finance
Hoth Therapeutics (NASDAQ: HOTH) Stock Skyrockets Following Approval of HT-001 Phase 2a Human Trials - ABBO News
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Hoth Therapeutics ($HOTH) Advances to Phase 2a Trials with New Skin Toxicity Treatment - BP Journal
Hoth Therapeutics Inc (HOTH) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Gold Moves Higher; Science Applications International Posts Upbeat EarningsChargePoint Hldgs (NYSE:CHPT) - Benzinga
Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient - MarketWatch
Dow Tumbles 1%; US Crude Oil Stocks FallSify Technologies (NASDAQ:SIFY) - Benzinga
HOTH’s valuation metrics: A comprehensive analysis - US Post News
Hoth reports rapid symptom relief in cancer treatment - Investing.com India
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - StockTitan
US Stocks Edge Higher; Jobless Claims Fall To 227,000 - Benzinga
Hoth reports rapid symptom relief in cancer treatment - Investing.com
Hoth Therapeutics jumps as skin toxicity drug shows promise in one patient - XM
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - StockTitan
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 - PR Newswire
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):